Simulations Plus SLP announced the launch of GastroPlus X (GPX), which is its latest platform for physiologically based pharmacokinetics and biopharmaceutics (PBPK/PBBM) modeling and simulation. The ...
Simulations Plus, Inc. SLP shares are trading lower on Wednesday as the company announced a collaboration with NVIDIA Corp ...
Co-development initiatives to advance next-generation workflows, accelerate adoption, and expand the role of AI within model-informed drug development Simulations Plus, Inc. (Nasdaq: SLP) ...
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and ...
Simulations Plus Inc (NASDAQ:SLP) is among the best medical AI stocks to buy now. On March 26, Simulations Plus announced collaboration programs for AI-enabled modeling in drug development.
More than 1,400 participants across 65+ countries underscores accelerating adoption of model-informed workflows and growing demand for applied modeling expertise RESEARCH TRIANGLE PARK, ...
Objective to define best practices for the use of novel PBK modeling strategies to support animal-free safety assessment of new chemicals LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results